Literature Analysis of Clinical Research Progress of Chinese Patent Medicine in the Treatment of Threatened Abortion
OBJECTIVE:To integrate and analyze the information and clinical research progress of Chinese patent medicine in the treatment of threatened abortion based on literature analysis,so as to provide a strong basis for the future research theme and clinical application of Chinese patent medicine in the treatment of threatened abortion.METHODS:Through a comprehensive search of the DRUGDATAEXPY and"Three Major Catalogs"such as Pharmacopoeia of the People's Republic of China(Volume 1,2020 Edition),National Essential Medicine List(2018 Edition),and National Basic Medical Insurance,Occupational Injury Insurance and Maternity Insurance Catalogue(2020 Edition),Chinese patent medicine in the treatment of threatened abortion were retrieved.Drug instructions were used as the screening criterion to include Chinese patent medicine mentioned to have a tranquilizing effect and used in the treatment of threatened abortion.Literature related to Chinese patent medicine was searched in four Chinese databases(CNKI,VIP,Wanfang Data and SinoMed)and four English databases(PubMed,Embase,the Cochrane Library and Web of Science).Literature information meeting the inclusion criteria was extracted,and then displayed in the form of text description and visual charts after statistical analysis.RESULTS:Totally 17 kinds of Chinese patent medicines were enrolled,including 289 articles.Gushenantai pills gained the highest attention(79 articles),followed by Yunkang preparation(64 articles),and Zishenyutai pills(63 articles).Since 1998,the overall attention of threatened abortion research was on the rise,clinical studies conducted in 26 provinces(autonomous regions and municipalities)in China.Of the 285 clinical studies,a total of 153 studies(53.68%)had a sample size of 51 to 100 cases,with the most being load tests,constituting a total of 255 studies(89.47%).Currently,there is no unified standard for clinical efficacy assessment,and 113 studies(39.65%)involve drug safety issues.CONCLUSIONS:The clinical appropriateness of Chinese patent medicine in the treatment of threatened abortion is well established,and research results are increasing.However,there is still a lack of relevant high-quality clinical studies,and it is hoped that investment in this area can be increased in the future,with a view to providing a scientific and reliable basis for the clinical application of Chinese patent medicine in the treatment of threatened abortion.
国家科技期刊平台
NSTL
万方数据
